Abstract:Aim: Upadacitinib is a Janus kinase/signal transducers and activators of transcription (JAKs) of cytoplasmic tyrosine kinase that has been proven to be effective in treating inflammatory conditions and various immunological diseases/disorders, including rheumatoid arthritis. Tofacitinib and ruxolitinib, which are members of this drug's first generation, did not affect JAK1/JAK3 or JAK1/JAK2 receptors specifically due to a lack of subtype selectivity. As far as we are aware, there is currently no method for the… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.